DEADLINES

• Regular Abstracts

Monday, February 22, 2027, at 11:59 PM ET.

This deadline will not be extended. NOTE: Abstracts including titles, content, and authors, cannot be edited after the May 26 deadline. Acceptance notifications will be sent in late July or early August.

All accepted abstracts will be published at the start of the meeting as submitted in an online supplement to the journal Neuro-Oncology Pediatrics. Edits to abstracts or abstract titles cannot be made after the February 22 deadline. Abstract submitters should carefully check your abstract including titles and authors for content errors, spelling, names, etc. before submitting. SNO neither proofreads for nor corrects spelling, typographical, grammatical, or scientific errors.

• Late-Breaking Abstract Deadline:

Monday, February 22, 2027, at 11:59pm ET (Placeholder)

Friday, April 9, 2027, at 5:00 PM ET (Final).

Only abstracts related to late-phase clinical trials will be accepted for late breaking consideration. A placeholder abstract must be submitted by the initial February 22 deadline. Submitters who do not submit a placeholder abstract by the February 22 deadline will not be allowed to submit a late-breaking abstract. Before submitting in the late-breaking abstract category, please read the important late breaking guidelines.

• Withdrawal Deadline:

Tuesday, April 13, 2027, at 5:00 PM ET.

Once the accepted abstracts are submitted to the journal for publication, requests for withdrawals cannot be processed.

• Presenter Registration Deadline:

Presenters will be required to register for the meeting by the designated presenter registration deadline. All presenters, oral and posters, must be present in person at the meeting and must register for the meeting by the deadline.

PERMISSIONS

• All accepted abstracts will be published at the start of the meeting as submitted in the journal Neuro-Oncology Pediatrics. Submitters will be required to provide permission to publish. There are no exceptions.
• All presentations will be recorded and will be made available on SNO’s website for approximately one year following the meeting. Submitters will be required to provide permission to record. There are no exceptions.
• The abstract submitter must confirm that all authors have approved the abstract submission.
• The abstract submitter must confirm that the presenter or another author will register for and present the accepted abstract at the meeting.
• Presenters will be given full credit for their presentations. For the purpose of Neuro-Oncology, Neuro-Oncology Practice, Neuro-Oncology Advances, Neuro-Oncology Pediatrics and other scholarly journals, presentation in either of these forums is not considered “prior publication.”

REGISTRATION REQUIREMENTS

• All listed abstract presenters (oral and poster) MUST register for the meeting by {{ADD DEADLINE}}. If the listed presenter is not registered by the registration deadline, the abstract will be withdrawn from the meeting.
• Presenters must present their abstract in person at the meeting. Virtual or pre-recorded presentations will not be possible.
• If you have a presenter change, you must notify Tara Mammoser at tara@soc-neuro-onc.org via email.

EMBARGO DETAILS

• The embargo will be lifted for regular abstracts on June 14, 2027, at 10:00 AM ET. Late breaking abstracts will be released the day of presentation.
• Press releases may be issued after the embargo is lifted. However, we ask that you do not release the presentation slides or posters until after the presentation at the meeting.

SUBMITTER/PRESENTER RESPONSIBILITES

• Presenters using a third party to create slides and/or posters are responsible for communicating presentation details and specifications with the third party.
• Poster presenters will be required to submit an electronic version of their traditional poster they will hang and display at the meeting. The electronic version will be available for attendees to view on the SNO website for approximately one year following the meeting.
• Initial communication will be sent to the abstract submitter and later to the presenter (if different than the submitter).
• Communication regarding your presentation and other details will be sent to the email address provided by the submitter. Please be sure to verify the submitters and presenters email addresses. SNO is not responsible for verifying email addresses.
• There may be only one presenter per abstract.

CONTENT OF ABSTRACTS

Abstract submitters should carefully review their abstract for content errors (spelling, names, etc.) before submitting. SNO neither proofreads for nor corrects spelling, typographical, grammatical, or scientific errors. Accepted abstracts will be published as submitted in the journal Neuro-Oncology Pediatrics. Abstract edits, including author additions, cannot be made after the February 22 deadline.

• Abstract Title
• Should be sentence case (i.e., only the first letter of the sentence should be capitalized).
• Should be plain text (no html).
• Word Limit: 75 words.
• Abstract Body
• Figures and tables are not allowed.
• If sub-headers are used (i.e., Background, Methods, Results, Conclusions), they should be included in the paragraph and not bold.
• Abstracts should be data-driven and must include this information in the body of the abstract.
• Word Limit: 300 words.
• Authors
• There can only be one presenting author per abstract submission. If the listed presenting author is unable to present, a co-author will be allowed to present in their place. All presenter changes must be sent via email to Tara Mammoser at tara@soc-neuro-onc.org.
• Enter the names of authors in the order in which you wish them to appear on the meeting website and in the journal.
• Communication will be sent to the email addresses provided by the submitter. The submitter should verify the entered email addresses. SNO is not responsible for verifying email addresses.
• Submitters should verify spelling and institutional affiliations of authors. SNO neither proofreads for nor corrects spelling or institutional affiliation errors.
• Author Limit: 50 authors with a maximum of 2 affiliations per author.
• Authors cannot be edited or added after the February 22 deadline.

Abstract Submission Categories

• Atypical Teratoid Rhabdoid Tumor
• Biological Correlates, Biomarkers
• Cancer Neuroscience
• Craniopharyngioma
• Diffuse Midline Glioma, Diffuse Intrinsic Pontine Glioma
• Diversity, Equity, and Inclusion
• Early Phase Clinical Trials/Developmental Therapeutics
• Embryonal Tumor with Multilayered Rosettes (ETMR), Other Embryonal Tumors, Rare tumors
• Ependymoma
• Epidemiology
• Genomics, Epigenomics, Metabolomics
• Germ Cell Tumors
• High Grade Glioma
• Imaging
• Immune-, Cell-, Gene-, and Viral-Based Therapies
• Low Grade Glioma
• Medulloblastoma
• Neurofibromatosis and other Cancer Predisposition Syndromes
• Neuropsychology, Quality of Life, Survivorship
• Neurosurgery, Drug Delivery
• Nursing, Social Work, Patient Support
• Others (not fitting any other category)
• Palliative Care
• Pathology, Classification
• Pediatric Neuro-Oncology in Low/Middle Income Countries
• Preclinical Models, Drug Discovery
• Radiation Oncology
• Tumor Biology, Stem Cells, Models
• Late Breaking (late breaking submissions must be late phase clinical trials)